A retrospective analysis of overall response and survival to 1st+ salvage therapy in T-cell and 2nd+ salvage therapy in B-cell pediatric acute lymphoblastic leukemia (20180065) (Retrospective pediatric ALL retrospective response)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/45070
• EU PAS number:
  EUPAS27121
• Study ID:
  45070
• Official title and acronym:
  A retrospective analysis of overall response and survival to 1st+ salvage therapy in T-cell and 2nd+ salvage therapy in B-cell pediatric acute lymphoblastic leukemia (20180065) (Retrospective pediatric ALL retrospective response)
• DARWIN EU® study:
  No
• Study countries:
  Australia

  Canada

  Germany

  Italy

  United States
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned: 01/08/2019

Actual: 01/08/2019

Study start date

Planned: 01/12/2019

Actual: 01/12/2019

Data analysis start date

Planned: 27/06/2024

Actual: 27/06/2024

Date of final study report

Planned: 31/12/2024

Actual: 06/11/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable